Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Diseases caused by fungi can occur in healthy people, but immunocompromised patients are the major risk group for invasive fungal infections. Cases of fungal resistance and the difficulty of treatment make fungal infections a public health problem. This review explores mechanisms used by fungi to promote fungal resistance, such as the mutation or overexpression of drug targets, efflux and degradation systems, and pleiotropic drug responses. Alternative novel drug targets have been investigated; these include metabolic routes used by fungi during infection, such as trehalose and amino acid metabolism and mitochondrial proteins. An overview of new antifungal agents, including nanostructured antifungals, as well as of repositioning approaches is discussed. Studies focusing on the development of vaccines against antifungal diseases have increased in recent years, as these strategies can be applied in combination with antifungal therapy to prevent posttreatment sequelae. Studies focused on the development of a pan-fungal vaccine and antifungal drugs can improve the treatment of immunocompromised patients and reduce treatment costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These lipopeptides act on fungal cell walls by specific inhibition of 1,3-β-Dglucan synthase, which is responsible for the biosynthesis of β-1,3-glucan, the key fungal cell wall component [19].”
BackgroundAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593 · cited 2×
“Screening of libraries of synthetic small molecules or natural products is one of the most employed methods to identify drugs [99, 102, 103] and represents the vast majority of the available antibiotics for clinical use [99, 115–117].”
BackgroundAmphotericin forms an extramembranous and fungicidal sterol sponge
Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1496 · Cited by 528
Fradin, C., De Groot, P., MacCallum, D., Schaller, M., Klis, F., Odds, F. C., & Hube, B. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04557.x · Cited by 455
Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445
A novel glyco-conjugate vaccine against fungal pathogens
Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050749 · Cited by 442
Niche-specific regulation of central metabolic pathways in a fungal pathogen
Barelle, C. J., Priest, C. L., MacCallum, D. M., Gow, N. A. R., Odds, F. C., & Brown, A. J. P. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00676.x · Cited by 336
A neglected epidemic: Fungal infections in HIV/AIDS
Armstrong-James, D., Meintjes, G., & Brown, G. D. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.01.001 · Cited by 325 · cited 1×
“Despite these alarming statistics, the impact of fungal infections on human health has generally been neglected [97].”
BackgroundGarcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 1×
“tropicalis produces less ROS and alters mitochondrial activity [46].”
BackgroundMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Echinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Mesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
Rajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. J., & Ramage, G. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.018 · Cited by 228 · cited 2×
“The overall inefficiency and high toxicity of current antifungal therapies are also noteworthy [5].”
BackgroundElevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · cited 2×
“This promising antifungal has recently entered clinical trials [90].”
BackgroundSystems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148 · cited 3×
“For the FKS2 subunit, the substitutions Ser641 and Ser645 strongly reduce enzyme activity, causing a pronounced resistance phenotype [20, 31].”
BackgroundConfronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147
da Silva, A. R., de Andrade Neto, J. B., da Silva, C. R., Campos, R. D. S., Costa Silva, R. A., Freitas, D. D., do Nascimento, F. B. S. A., de Andrade, L. N. D., Sampaio, L. S., Grangeiro, T. B., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01846-15 · Cited by 139 · cited 1×
“They can be obtained as metabolites of plants, insects, animals, and microorganisms [104, 105, 107] as the first-line arsenal to combat infections.”
BackgroundMultidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
Krappmann, S., Bignell, E. M., Reichard, U., Rogers, T., Haynes, K., & Braus, G. H. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04015.x · Cited by 133 · cited 1×
“fumigatus virulence in a murine model of pulmonary aspergillosis [57, 58].”
BackgroundForastiero, A., Mesa-Arango, A. C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J. F., Grimalt, J. O., Gomez-Lopez, A., Cuesta, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-13 · Cited by 131 · cited 1×
“In Candida tropicalis, low ergosterol content in the membrane is associated with reduced susceptibility to amphotericin B [44].”
BackgroundFungal metabolism in host niches
Brock, M. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.05.004 · Cited by 115 · cited 1×
“fumigatus relies more on the methylcitrate cycle (MCC) for survival in mammalian hosts [79].”
BackgroundGrahl, N., Demers, E. G., Lindsay, A. K., Harty, C. E., Willger, S. D., Piispanen, A. E., & Hogan, D. A. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005133 · Cited by 111 · cited 1×
“The RAS pathway interacts with complexes I and IV but not with complex II or alternative oxidase [65].”
BackgroundThe role of the Aspergillus fumigatusareA gene in invasive pulmonary aspergillosis
Hensel, M., Arst Jr, H. N., Aufauvre-Brown, A., & Holden, D. W. (1998) · Molecular and General Genetics MGG · doi:10.1007/s004380050767 · Cited by 102
System-level impact of mitochondria on fungal virulence: to metabolism and beyond
Calderone, R., Li, D., & Traven, A. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov027 · Cited by 101
Koselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83
Robbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Neubauer, M., Zhu, Z., Penka, M., Helmschrott, C., Wagener, N., & Wagener, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13167 · Cited by 76 · cited 1×
“In contrast,fissionmutants showed impaired sporulation and are not essential for virulence [70].”
BackgroundDisulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide
Hein, K. Z., Takahashi, H., Tsumori, T., Yasui, Y., Nanjoh, Y., Toga, T., Wu, Z., Grötzinger, J., Jung, S., Wehkamp, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511197112 · Cited by 74
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin
Fekkar, A., Meyer, I., Brossas, J. Y., Dannaoui, E., Palous, M., Uzunov, M., Nguyen, S., Leblond, V., Mazier, D., & Datry, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02037-12 · Cited by 56
Emergence of Candida tropicalis resistant to caspofungin
Pasquale, T., Tomada, J. R., Ghannoun, M., Dipersio, J., & Bonilla, H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm453 · Cited by 56
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection
Shields, R. K., Nguyen, M. H., Press, E. G., Cumbie, R., Driscoll, E., Pasculle, A. W., & Clancy, C. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01973-15 · Cited by 55
She, X., Khamooshi, K., Gao, Y., Shen, Y., Lv, Y., Calderone, R., Fonzi, W., Liu, W., & Li, D. (2015) · Cellular Microbiology · doi:10.1111/cmi.12438 · Cited by 51 · cited 1×
“The mutants for these molecules presented low ATP synthesis and respiration, defects in complex I assembly, and avirulence in a mouse model, which confirm these two proteins as interesting targets for antifungal development [66, 67].”
BackgroundJensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47
Functional diversity of complex I subunits in Candida albicans mitochondria
Li, D., She, X., & Calderone, R. (2016) · Current Genetics · doi:10.1007/s00294-015-0518-6 · Cited by 27 · cited 2×
“The mutants for these molecules presented low ATP synthesis and respiration, defects in complex I assembly, and avirulence in a mouse model, which confirm these two proteins as interesting targets for antifungal development [66, 67].”
BackgroundAmich, J., & Bignell, E. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.06.003 · Cited by 26 · cited 2×
“Growing knowledge suggests that biosynthetic pathways have purposes beyond nutritional requirements; additional functions may exists that could be even more important for pathogenicity [59].”
BackgroundUeno, K., Namiki, Y., Mitani, H., Yamaguchi, M., & Chibana, H. (2011) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2011.00728.x · Cited by 17
Cited by
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
“Thus, common drugs are ineffective and in-adequate to deal with this situation [157–160].”
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32
Metadata
- Authors
- Parente-Rocha, J. A., Bailão, A. M., Amaral, A. C., Taborda, C. P., Paccez, J. D., Borges, C. L., & Pereira, M.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-16
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2625675304
- Cited by
- 94
- References
- 46
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.